BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 246 filers reported holding BIO-TECHNE CORP in Q1 2015. The put-call ratio across all filers is - and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,218,622 | +1.4% | 47,284 | +322.9% | 0.22% | -10.0% |
| Q3 2022 | $3,175,000 | +1.3% | 11,181 | +23.7% | 0.24% | -16.7% |
| Q2 2022 | $3,133,000 | +5494.6% | 9,041 | +6801.5% | 0.29% | +5660.0% |
| Q1 2022 | $56,000 | -81.2% | 131 | -89.1% | 0.01% | -85.3% |
| Q3 2020 | $298,000 | +46.8% | 1,203 | +30.1% | 0.03% | +70.0% |
| Q4 2019 | $203,000 | +227.4% | 925 | +208.3% | 0.02% | +233.3% |
| Q2 2019 | $62,000 | -95.4% | 300 | -96.8% | 0.01% | -95.4% |
| Q4 2018 | $1,339,000 | +19028.6% | 9,254 | +18408.0% | 0.13% | – |
| Q2 2018 | $7,000 | +16.7% | 50 | -12.3% | 0.00% | -100.0% |
| Q2 2017 | $6,000 | -91.0% | 57 | -91.4% | 0.00% | -85.7% |
| Q1 2017 | $67,000 | +59.5% | 662 | +39.7% | 0.01% | 0.0% |
| Q4 2015 | $42,000 | +740.0% | 474 | +717.2% | 0.01% | +600.0% |
| Q2 2015 | $5,000 | -89.8% | 58 | -88.3% | 0.00% | -91.7% |
| Q1 2015 | $49,000 | -31.9% | 496 | -36.8% | 0.01% | -47.8% |
| Q4 2014 | $72,000 | – | 785 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $13,206,000 | 5.33% |
| Montanaro Asset Management Ltd | 101,950 | $28,954,000 | 4.43% |
| Jackson Square Partners, LLC | 521,991 | $148,245,000 | 3.89% |
| Sandhill Capital Partners LLC | 119,671 | $33,987,000 | 3.88% |
| STONE RUN CAPITAL, LLC | 22,055 | $6,264,000 | 3.38% |
| Ownership Capital B.V. | 610,466 | $173,372,000 | 3.35% |
| Brown Capital Management | 823,303 | $233,818,000 | 3.28% |
| DF DENT & CO INC | 671,348 | $190,663,000 | 2.94% |
| Westwind Capital | 27,931 | $7,932,000 | 2.78% |
| MAIRS & POWER INC | 673,620 | $191,308,000 | 2.41% |